Study Finds 189 Young-Onset Colon Tumors Show Stromal Traits Tied to Drug Resistance
Updated
Updated · The Washington Post · Nov 1
Study Finds 189 Young-Onset Colon Tumors Show Stromal Traits Tied to Drug Resistance
3 articles · Updated · The Washington Post · Nov 1
Summary
Researchers analyzing 189 frozen colorectal tumor samples found cancers in patients under 50 carry distinct cellular features that may help explain poorer responses to treatment and greater spread.
The clearest difference was a higher presence of stromal cells in younger patients’ tumors; those connective-tissue cells can shield tumors from immune attack and drugs and have been linked to chemotherapy resistance in other cancers.
Dozens of genes were also expressed differently in younger versus older patients, including some tied to metastasis, though several altered genes still have unknown functions.
Outside experts called the findings promising but cautioned the study does not prove these tumor differences directly cause more aggressive disease.
The work could guide future precision treatments and, over time, improve understanding of precancerous changes and screening as early-onset colorectal cancer keeps rising despite overall U.S. declines in incidence and mortality.
If early-onset colon cancer is biologically distinct, are current treatments inadvertently failing younger patients by treating them like older adults?
How might hidden changes in our gut microbiome be rewiring young adults' cells to trigger aggressive, treatment-resistant colon cancers?